Literature DB >> 25900577

Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia.

Rolla F Abu-Arja1, Leah R Chernin2, Ghada Abusin3, Jeffery Auletta1, Linda Cabral4, Rachel Egler4, Hans D Ochs5, Troy R Torgerson, Jesus Lopez-Guisa5, Robert W Hostoffer2, Haig Tcheurekdjian2, Kenneth R Cooke6.   

Abstract

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency characterized by marked reduction in all classes of serum immunoglobulins and the near absence of mature CD19(+) B-cells. Although malignancy has been observed in patients with XLA, we present the first reported case of acute myeloid leukemia (AML) in a patient with XLA. We also demonstrate the complete correction of the XLA phenotype following allogeneic hematopoietic cell transplantation for treatment of the patient's leukemia.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  X-linked agammaglobulinemia; acute myeloid leukemia; stem cell transplantation

Mesh：

Substances：

Year:  2015        PMID： 25900577      PMCID： PMC4876715          DOI： 10.1002/pbc.25554

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  21 in total

1.  Stem cell transplants for patients with X-linked agammaglobulinemia.

Authors:  Vanessa Howard; Laurie A Myers; David A Williams; Gary Wheeler; E Victoria Turner; John M Cunningham; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2003-05       Impact factor: 3.969

2.  Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.

Authors:  Lauri M Burroughs; Troy R Torgerson; Rainer Storb; Paul A Carpenter; David J Rawlings; Jean Sanders; Andrew M Scharenberg; Suzanne Skoda-Smith; Janet Englund; Hans D Ochs; Ann E Woolfrey
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

3.  Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.

Authors:  S Müller; P Sideras; C I Smith; K G Xanthopoulos
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

4.  The health status and quality of life of adults with X-linked agammaglobulinemia.

Authors:  Vanessa Howard; Jeffrey M Greene; Savita Pahwa; Jerry A Winkelstein; John M Boyle; Mehmet Kocak; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2005-12-22       Impact factor: 3.969

Review 5.  Adverse effects of human immunoglobulin therapy.

Authors:  E Richard Stiehm
Journal:  Transfus Med Rev       Date:  2013-07-06

6.  Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.

Authors:  E Holinski-Feder; M Weiss; O Brandau; K B Jedele; B Nore; C M Bäckesjö; M Vihinen; S R Hubbard; B H Belohradsky; C I Smith; A Meindl
Journal:  Pediatrics       Date:  1998-02       Impact factor: 7.124

7.  The quality of life of children and adolescents with X-linked agammaglobulinemia.

Authors:  Annarosa Soresina; Renata Nacinovich; Monica Bomba; Morena Cassani; Anna Molinaro; Antonella Sciotto; Silvana Martino; Fabio Cardinale; Domenico De Mattia; Caterina Putti; Rosa Maria Dellepiane; Leonardo Felici; Giovanni Parrinello; Francesca Neri; Alessandro Plebani
Journal:  J Clin Immunol       Date:  2008-12-17       Impact factor: 8.317

8.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

9.  Reconstitution of B cell function in murine models of immunodeficiency.

Authors:  Andrea S Porpiglia; Jurg Rohrer; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2003-05       Impact factor: 3.969

10.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.

Authors:  D Vetrie; I Vorechovský; P Sideras; J Holland; A Davies; F Flinter; L Hammarström; C Kinnon; R Levinsky; M Bobrow
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962
View more
  8 in total

1.  [Structure and function of B-cell linker and its role in the development of B cell-related diseases].

Authors:  Bin Xiao; Jiaying Li; Mengsi Zhou; Xiaoqing Li; Xiaoyan Huang; Jianfeng Hang; Zhaohui Sun; Linhai Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

2.  Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.

Authors:  Di Sun; Jennifer R Heimall; Matthew J Greenhawt; Nancy J Bunin; Marcus S Shaker; Neil Romberg
Journal:  JAMA Pediatr       Date:  2022-02-01       Impact factor: 16.193

3.  Nodular regenerative hyperplasia in X-linked agammaglobulinemia: An underestimated and severe complication.

Authors:  Cristiane J Nunes-Santos; Christopher Koh; Anjali Rai; Keith Sacco; Beatriz E Marciano; David E Kleiner; Jamie Marko; Jenna R E Bergerson; Michael Stack; Maria M Rivera; Gregory Constantine; Warren Strober; Gulbu Uzel; Ivan J Fuss; Luigi D Notarangelo; Steven M Holland; Sergio D Rosenzweig; Theo Heller
Journal:  J Allergy Clin Immunol       Date:  2021-06-01       Impact factor: 10.793

Review 4.  X-linked Agammaglobulinemia.

Authors:  Deepti Suri; Amit Rawat; Surjit Singh
Journal:  Indian J Pediatr       Date:  2016-02-24       Impact factor: 5.319

5.  Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.

Authors:  Kazuhiro Ikegame; Kohsuke Imai; Motoi Yamashita; Akihiro Hoshino; Hirokazu Kanegane; Tomohiro Morio; Katsuji Kaida; Takayuki Inoue; Toshihiro Soma; Hiroya Tamaki; Masaya Okada; Hiroyasu Ogawa
Journal:  J Hematol Oncol       Date:  2016-02-13       Impact factor: 17.388

6.  Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for TP53 Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia.

Authors:  Menno C van Zelm; Marsus Pumar; Peter Shuttleworth; Pei M Aui; Joanne M Smart; Andrew Grigg; Julian J Bosco
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

7.  A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.

Authors:  Shu-Ping Han; Yung-Feng Lin; Hui-Ying Weng; Shih-Feng Tsai; Lin-Shien Fu
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

8.  Clinical and Genetic Profile of X-Linked Agammaglobulinemia: A Multicenter Experience From India.

Authors:  Amit Rawat; Ankur Kumar Jindal; Deepti Suri; Pandiarajan Vignesh; Anju Gupta; Biman Saikia; Ranjana W Minz; Aaqib Zaffar Banday; Rahul Tyagi; Kanika Arora; Vibhu Joshi; Sanjib Mondal; Jitendra Kumar Shandilya; Madhubala Sharma; Mukesh Desai; Prasad Taur; Ambreen Pandrowala; Vijaya Gowri; Sneha Sawant-Desai; Maya Gupta; Aparna Dhondi Dalvi; Manisha Madkaikar; Amita Aggarwal; Revathi Raj; Ramya Uppuluri; Sagar Bhattad; Ananthvikas Jayaram; Harsha Prasad Lashkari; Liza Rajasekhar; Deenadayalan Munirathnam; Manas Kalra; Anuj Shukla; Ruchi Saka; Rajni Sharma; Ravinder Garg; Kohsuke Imai; Shigeaki Nonoyama; Osamu Ohara; Pamela P Lee; Koon Wing Chan; Yu-Lung Lau; Surjit Singh
Journal:  Front Immunol       Date:  2021-01-15       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.